The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Immunocytochemical markers in stage I lung cancer: relevance to prognosis.
Abstract
PURPOSE: This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BCl2; p53; and angiogenesis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. RESULTS: The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as an independent predictive factor for survival. Bcl2-positive tumors showed a better time to recurrence (P = .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pT1N0, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously. CONCLUSION: Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A New International Staging System for Lung Cancer
Mountain, C. F. (1986) · Chest · doi:10.1378/chest.89.4_supplement.225s · Cited by 1,659
Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schlüuter, C., Galle, J., & Gerdes, J. (1992) · The Journal of Pathology · doi:10.1002/path.1711680404 · Cited by 1,447
Prognosis and survival in resected lung carcinoma based on the new international staging system
Naruke, T., Goya, T., Tsuchiya, R., & Suemasu, K. (1988) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)35243-2 · Cited by 688
Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.
Pezzella, F., Tse, A. G. D., Cordell, J. L., Pulford, K. A. F., Gatter, K. C., & Mason, D. Y. (1990) · Europe PMC (PubMed Central) · Cited by 595
Self-citationAccumulation of p53 protein correlates with a poor prognosis in human lung cancer.
Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., & Doshi, H. M. (1992) · PubMed · Cited by 383
Adjuvant treatment of stage I lung cancer with high-dose vitamin A.
Pastorino, U., Infante, M., Maioli, M., Chiesa, G., Buyse, M., Firket, P., Rosmentz, N., Clerici, M., Soresi, E., & Valente, M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1216 · Cited by 350
Self-citationHung, J. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310056030 · Cited by 339
Harpole, D. H., Herndon, J. E., Wolfe, W. G., Iglehart, J. D., & Marks, J. R. (1995) · PubMed · Cited by 290
Cited by
Epidermal growth factor receptor family in lung cancer and premalignancy
Franklin, W. A., Veve, R., Hirsch, F. R., Helfrich, B. A., & Bunn, P. A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31520 · Cited by 306
Meert, A.-P., Martin, B., Delmotte, P., Berghmans, T., Lafitte, J.-J., Mascaux, C., Paesmans, M., Steels, E., Verdebout, J.-M., & Sculier, J.-P. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00296502 · Cited by 264
Dome, B., Timar, J., Dobos, J., Meszaros, L., Raso, E., Paku, S., Kenessey, I., Ostoros, G., Magyar, M., Ladanyi, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4654 · Cited by 184
Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making
Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59
Non‐angiogenic tumours unveil a new chapter in cancer biology
Pezzella, F., & Gatter, K. (2015) · The Journal of Pathology · doi:10.1002/path.4474 · Cited by 18
Self-citation
Metadata
- Authors
- Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incarbone, M., Sozzi, G., Buyse, M., Menard, S., Pierotti, M., & Rilke, F.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-08
- Volume
- 15
- Issue
- 8
- Pages
- 2858-2865
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1960304662
- Cited by
- 302
- References
- 22
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunocytochemical markers in stage I lung cancer: relevance to prognosis. https://app.cochat.ai/papers/10.1200/jco.1997.15.8.2858
- The paper
- Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incarbone, M., Sozzi, G., Buyse, M., Menard, S., Pierotti, M., & Rilke, F. (1997). Immunocytochemical markers in stage I lung cancer: relevance to prognosis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1997.15.8.2858
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
